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A B S T R A C T
Phosphatidylinositol 4,5-bisphosphate (PIP2) acts as substrate and unmodified ligand for Gq-protein-coupled
receptor signalling in vascular smooth muscle cells (VSMCs) that is central for initiating contractility. The
present work investigated how PIP2 might perform these two potentially conflicting roles by studying the effect
of myristoylated alanine-rich C kinase substrate (MARCKS), a PIP2-binding protein, on vascular contractility in
rat and mouse mesenteric arteries. Using wire myography, MANS peptide (MANS), a MARCKS inhibitor, pro-
duced robust contractions with a pharmacological profile suggesting a predominantly role for L-type (CaV1.2)
voltage-gated Ca2+ channels (VGCC). Knockdown of MARCKS using morpholino oligonucleotides reduced
contractions induced by MANS and stimulation of α1-adrenoceptors and thromboxane receptors with methox-
amine (MO) and U46619 respectively. Immunocytochemistry and proximity ligation assays demonstrated that
MARCKS and CaV1.2 proteins co-localise at the plasma membrane in unstimulated tissue, and that MANS and
MO reduced these interactions and induced translocation of MARCKS from the plasma membrane to the cytosol.
Dot-blots revealed greater PIP2 binding to MARCKS than CaV1.2 in unstimulated tissue, with this binding profile
reversed following stimulation by MANS and MO. MANS evoked an increase in peak amplitude and shifted the
activation curve to more negative membrane potentials of whole-cell voltage-gated Ca2+ currents, which were
prevented by depleting PIP2 levels with wortmannin. This present study indicates for the first time that MARCKS
is important regulating vascular contractility and suggests that disinhibition of MARCKS by MANS or vaso-
constrictors may induce contraction through releasing PIP2 into the local environment where it increases vol-
tage-gated Ca2+ channel activity.
1. Introduction
It is well-established that phosphatidylinositol 4,5-bisphosphate
(PIP2) acting as a substrate for Gq-protein-coupled receptor signalling
in vascular smooth muscle cells (VSMCs) has a central role in vaso-
constrictor-mediated contractility [1,2]. Gq-protein receptor-mediated
phospholipase C (PLC) activity leads to PIP2 hydrolysis and generation
of inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG) which
drive multiple pathways that increase intracellular Ca2+ concentration
to induce contraction. In particular, IP3-mediated Ca2+ release from
sarcoplasmic reticulum stores and DAG-mediated signal transduction
pathways regulate an array of cation, Cl−, and K+ channel subtypes to
induce membrane depolarisation and activation of voltage-gated Ca2+
channels (VGCC) to produce Ca2+ influx and contraction [1,2].
There is also considerable evidence that, in addition to its classical
role as a substrate for Gq-mediated PLC activity, PIP2 acts as an un-
modified ligand to regulate proteins involved in modulating vascular
contractility including ion channels involved in regulating membrane
potential and VGCC activity [3–10]. This raises an important question
in vascular biology; how can PIP2 act as both substrate and unmodified
ligand to regulate different cellular pathways involved in regulating
contractility? An explanation is the existence of independent pools of
PIP2, produced through localised formation and/or sequestration of
PIP2 at the plasma membrane [11]. Sequestration is an attractive hy-
pothesis as this would allow PIP2 to be retained in the local environ-
ment, thus preventing locally formed PIP2 from rapidly diffusing away
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from its site of action [11,12]. There are several natively unfolded
proteins which permit electrostatic interactions with PIP2 and therefore
sequestration, such as myristoylated alanine-rich C kinase (MARCKS),
growth-associated protein 43 (GAP43), and cytoskeleton-associated
protein 23 (CAP23) [13,14]. These proteins are proposed to act as PIP2
buffers or PIPmodulins to release PIP2 into the local environment fol-
lowing stimulation, allowing this source of PIP2 to act as an unmodified
ligand [11]. Hence PIP2 sequestration proteins may have important
roles in regulating vascular contractility by controlling PIP2-mediated
cellular processes. To date there have been no studies on the effect of
PIP2 sequestration proteins on vascular contraction, and therefore the
present study investigates the role of MARCKS in such a function.
MARCKS was chosen for this study since it is a ubiquitously expressed
protein whereas GAP43 and CAP23 are mainly found in neurones
[13,14].
Much is known about the chemical properties and cellular processes
that regulate MARCKS but relatively little is known about the function
of this PIP2-binding protein, although it has been associated with
neuronal development, cell migration and proliferation, and secretary
pathways [15–25]. MARCKS structure contains two important regions,
a myristoylated N-terminal region which weakly anchors it to the
plasma membrane, and an effector domain containing a sequence of
basic amino acids which form electrostatic interactions with PIP2 that
provide further stability at the plasma membrane. The effector domain
also acts as a protein kinase (PKC) substrate and a calmodulin (CaM)-
binding region, with PKC-dependent phosphorylation and CaM binding
both reducing electrostatic interactions with PIP2, leading to PIP2 re-
lease into the local environment and MARCKS to be translocated to the
cytosol. These properties define MARCKS as a reversible PIP2 buffer,
which can provide spatial sequestration and release of PIP2 to allow
targeted function.
Several studies have shown that MARCKS is expressed in VSMCs
where it has been proposed to have diverse functions including reg-
ulating PKC and CaM signalling [26], upregulation in neointima hy-
perplasia involving cell migration and proliferation [27–29], and
modulation of TRPC1 channel activity [30]. However, there have been
no studies on the role of MARCKS in regulating vascular contractility,
and therefore this was the aim of the present work. To achieve this, we
investigated the effect of the selective MARCKS inhibitor, MANS pep-
tide (MANS), and knockdown of MARCKS expression using morpholino
oligonucleotide technology [31,32]. MANS is a 24 amino acid sequence
that corresponds to the initial N-terminal myristoylated region of
MARCKS [33,34]. As such the MANS competes with endogenous
MARCKS for binding to the plasma membrane, which leads to MARCKS
being translocated into the cytosol and whilst releasing PIP2 into the
local environment. In addition, the hydrophobic myristate moiety
means MANS is highly cell permeant. MANS has been used in several
studies to reveal the role of MARCKS in mediating mucus secretion in
the airways [33,34], immune cell degranulation [35,36], amylase re-
lease [37], and lung cancer metastasis [38].
The present study provides the first evidence that MARCKS acting as
a plasma membrane PIP2 buffer has an important role in regulating
vascular contractility. Our findings suggest that disinhibition of
MARCKS by MANS or vasoconstrictors may induce contraction through
releasing PIP2 into the local environment where it increases voltage-
gated Ca2+ channel activity. These hypotheses provide provocative
novel ideas on cellular mechanisms governing vascular contraction,
which are likely to have important implications for understanding
physiological and pathological processes.
2. Methods
An expanded Methods sections is provided in the supplementary
data.
2.1. Animals
All animal procedures were carried out in accordance with guide-
lines laid down by St George's, University of London Animal Welfare
Committee and conform with the principles and regulations described
by the Service Project Licence: 70/8512. Male Wistar rats (8–12 weeks)
and 129-SV mice (6–9 weeks) were used for the purpose of this study.
Rats were supplied from Charles River, UK and 129-SV mice were bred
in the Biological Research Facility at St George's, University of London.
Animals were housed and maintained in standard sized plastic cages,
with a 12 h light-dark cycle, ambient room temperature of 18–20 °C,
relative humidity of approximately 50%, and water and lab rodent diet
(Specialist Dietary Services, UK) available ad libitum. Animals were
culled by cervical dislocation in accordance with the UK Animals
Scientific Procedures Act of 1986 and as revised by European Directive
2010/63/EU. Mesenteric arteries were dissected and cleaned of ad-
herent fat in physiological salt solution containing (mM): 126 NaCl, 6
KCl, 10 Glucose, 11 HEPES, 1.2 MgCl2, and 1.5 CaCl2, with pH adjusted
to 7.2 with 10 M NaOH. Mouse mesenteric arteries were used for wire
myography, mouse IP3 ELISA assay and proximity ligation assays. Rat
mesenteric arteries were used when a greater yield of protein from
tissue lysates or single VSMCs following tissue dispersal were required
for better experimental efficiency such as transfection for imaging PLC
activity, dot-blots and electrophysiological recordings.
2.2. Western blotting
Mouse and rat mesenteric arteries were homogenised with radio
immunoprecipitation assay lysis buffer containing a protease inhibitor
cocktail (Santa Cruz, USA) (see supplementary data for more details).
Samples were then loaded onto SDS-PAGE gels (4–12% Bis-Tris,
Invitrogen, UK), subjected to electrophoresis, and then transferred onto
a polyvinylidene fluoride membrane (Amersham Biosciences, UK). The
membrane was then probed with an anti-MARCKS antibody (1:100; SC-
6455, Santa Cruz, USA). Protein bands were visualized with a horse-
radish peroxidase-conjugated secondary antibody and enhanced che-
miluminescence reagents (Pierce Biotechnology, USA) for 1 min and
exposed to photographic films (Amersham Biosciences, UK).
2.3. Immunocytochemistry
Freshly dispersed VSMCs (see supplementary data for more details)
were fixed with 4% (w/v) paraformaldehyde for 15 min and permea-
bilised with PBS containing 0.25% (v/v) Triton X-100 for 10 min at
room temperature. Cells were then treated with phosphate-buffered
saline (PBS) containing 1% (w/v) bovine serum albumin (BSA) for 1 h at
room temperature, to block non-specific binding of antibodies.
Immunostaining was performed using an anti-MARCKS primary anti-
body (1:100; SC-6455, Santa Cruz, USA) and/or anti-CaV1.2 primary
antibody (1:100; ACC-003, Alomone, Israel) overnight at 4 °C. Cells
were then washed and incubated with a 488 fluorophore-conjugated
donkey anti-goat secondary antibody (1:1000; A-11055, Alexa Fluor,
UK) for 1 h at room temperature. Unbound secondary antibodies were
removed by washing with PBS, and nuclei were labelled with 4, 6-
diamidino-2-phenylindole (DAPI) mounting medium (Sigma, UK).
Control experiments were performed by replacing primary antibody
with goat serum (1:100; Sigma, UK) or omitting either primary or
secondary antibodies. Cells were imaged using a Zeiss LSM 510 laser
scanning confocal microscope (Carl Zeiss, Germany).
2.4. Isometric tension recordings
Segments of mouse superior mesenteric artery of about 2 mm in
length were mounted on a wire myograph (Danish Myo Technology,
Denmark) and endothelium was removed by rubbing the intima with a
human hair. Vessel segments were bathed in Krebs solution containing
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(mM): 118.4 NaCl, 4.69 KCl, 1.18 MgSO4, 1.22 KH2PO4, 25 NaHCO3, 10
glucose and 2 CaCl2, maintained at 37 °C and constantly aerated with
95% O2 and 5% CO2. Vessel segments were then normalised to 90% of
the internal circumference predicted to occur under a transmural
pressure of 100 mmHg [39]. Vessel segments were then equilibrated for
30 min and assessed for vessel viability with 60 mM KCl for 5 min.
Endothelium integrity was then assessed by stably pre-contracting
vessels with 10 μM methoxamine (MO) followed by 10 μM carbachol
(CCh). Carbachol-induced relaxation of ˂10% indicated successful re-
moval of the endothelium. Vessels were then equilibrated for 10 min
before the experimental protocol (see supplementary data for more
details).
2.5. Morpholino-mediated MARCKS knockdown
10 μM MARCKS-targeted (5’-GCACCCATGCTGGCTTCTTCAACAA-3′)
or scrambled morpholino (5’-GCACCgATcCTcGCTTgTTgAACAA) oligo-
nucleotides (Gene Tools Inc., USA) were mixed with Lipofectamine 2000
(Life Technologies, UK) in Opti-MEM (Life Technologies, UK) and left at
room temperature for 2 h. The Opti-MEM mix was then added to
Dulbecco's modified Eagle's medium (DMEM)/Nutrient Mixture F-12
(Life Technologies, UK), containing 1% Penicillin-Streptomycin (Sigma,
UK), and mouse superior mesenteric arteries were placed in this solution
at 37 °C for 48 h. Successful delivery of morpholino antisense oligonu-
cleotides was assessed using an Olympus 1 × 60 fluorescence inverted
microscope (Olympus, UK) with a Hamamatsu C4742–95 digital camera
and motorized stage (Hamamatsu Protonics, UK). Successful knock-down
of the protein and selectivity of MARCKS-targeted morpholino oligonu-
cleotides were assessed by western blotting and immunocytochemical
staining.
2.6. Transfection of PIP2 biosensors
GFP-PLCδ-PH was transfected into freshly dispersed rat mesenteric
artery VSMCs by electroporation using Nucleofector™ Technology
(Lonza, USA) as per manufacturer's instructions (see supplementary
data for more details). Following electroporation, cells were incubated
at 37 °C in 95% O2 and 5% CO2 in a humidified incubator for 48 h
before being imaged. Transfected cells were imaged at 37 °C in 95% O2
and 5% CO2 in a humidified chamber using a Nikon AR1 inverted
confocal microscope and associated software (Nikon Instruments, UK).
Excitation was produced by a 488 laser. Final images were produced
using PowerPoint (Microsoft XP; Microsoft, USA). Cell culture media
contained: Ca2+ free DMEM supplemented with 1% fetal bovine serum
(FBS), 1% Penicillin-Streptomycin, 2.5 mM L-Glutamine, 1 mM sodium
pyruvate and 1 μM wortmannin. 1% FBS was used to maintain VSMC
contractile phenotype and 1 μM wortmannin was used to prevent
contraction of VSMCs following pre-treatment with MANS or MO,
which prevents accurate imaging (as shown previously) [40,41].
2.7. Dot-blots
Rat mesenteric artery segments were dissected, divided into three,
and pre-treated with distilled water, 100 μM MANS, or 10 μM MO for
20 min at room temperature before extraction of protein (see supple-
mentary data for more details). Next, 500 μg of tissue lysate was im-
munoprecipitated (see supplementary data for more details) with either
an anti-MARCKS (SC-6455, Santa Cruz, USA) or anti-CaV1.2 primary
antibody (ACC-003, Alomone, Israel). Then, 15 μl of im-
munoprecipitated rat mesenteric artery tissue lysate was blotted on
nitrocellulose membranes (Amersham Biosciences, UK) and allowed to
dry before being blocked in 5% (w/v) milk powder in 0.05% (v/v)
PBST. Membranes were then incubated with an anti-PIP2 antibody
(1:200; SC-53412, Santa Cruz, USA) overnight at 4 °C. Visualisation was
performed with a donkey anti-mouse (1:10,000; LI-COR Biotechnology,
UK) fluorescently-conjugated secondary antibody, and imaged on the
Odyssey Infrared Imaging System (LI-COR Biotechnology, UK). Blot
intensities were analyzed with Image Studio, (version 3.0; LI-COR
Biotechnology, UK).
2.8. Whole-cell recording
Whole-cell patch clamp voltage-clamp and current clamp recordings
were conducted on freshly dispersed rat mesenteric artery VSMCs. In
voltage-clamp studies, VGCC activity was evoked by applying 300 ms
voltage steps from −80 mV to +40 mV at 10 mV intervals every 30 s
from a holding potential of −60 mV. A control current-voltage (I/V)
relationship curve was recorded before 100 μM MANS peptide was
added to the extracellular solution in the presence or absence of 20 μM
wortmannin, and then 3 μM nicardipine was used to confirm VGCC
channel activity. The extracellular solution contained (mM): 110 NaCl,
1 CsCl, 10 BaCl2, 1.2 MgCl2, 10 glucose, 10 HEPES, 0.1 DIDS, 0.1 GdCl2,
adjusted to pH 7.4 with 10 M NaOH. The internal patch pipette solution
contained (mM): 135 CsCl, 2.5 Mg-ATP, 0.1 GTP, 10 HEPES, 10 EGTA,
adjusted to pH 7.2 with 10 M CsOH. In current clamp studies, mem-
brane potential was recorded using an extracellular solution contained
(mM): 126 NaCl, 6 KCl, 10 Glucose, 11 HEPES, 1.2 MgCl2, and 1.5
CaCl2, with pH adjusted to 7.2 with 10 M NaOH and an internal patch
pipette solution contained (mM): 126 KCl, 5 NaCl, 2.5 Mg-ATP, 0.1
GTP, 10 HEPES, 1 BAPTA, adjusted to pH 7.2 with 10 M CsOH. Both
voltage-clamp and current clamp recordings were conducted once the
access resistance was<20 MΩ, filtered at 1 kHz, and sampled at 5 kHz.
All recordings were made at room temperature.
2.9. Data analysis
All data is expressed as mean ± standard error of mean for cor-
responding number (n) of animals. All statistical analysis was con-
ducted using GraphPad Prism software (Version 7.04, GraphPad, USA).
A P value of less than 5% (P < .05) was considered statistically sig-
nificant.
2.10. Materials
All chemicals and drugs were purchased from Sigma-Aldrich (Sigma
Chemical Co., Poole, UK) or Tocris (Tocris Biosciences, Bristol, UK).
MANS peptide (MANS) (Genemed Synthesis, USA) is a cell-permeable
synthetic peptide that is identical to the first 24 amino acids of the
MARCKS N-terminus [33,34] and contains the N-terminus myristic
moiety (MA-GAQFSKTAAKGEAAAERPGEAAVA, MA = N-terminal
myristate). GFP-PLCδ-PH was a gift from Professor Tobias Meyer
(Plasmid identification #21179; Addgene, USA). Drugs were dissolved
in distilled water or dimethyl sulfoxide (DMSO).
3. Results
3.1. MARCKS is expressed in mesenteric artery VSMCs
In our initial experiments we investigated the expression of
MARCKS in tissue lysates and freshly isolated VSMCs from mouse and
rat mesenteric arteries. Fig. 1A shows that western blot analysis re-
vealed a single protein band of about 60 kDa following immunoblotting
with an anti-MARCKS antibody, and Fig. 1B illustrates that distribution
of MARCKS staining using the same anti-MARCKS antibody was pre-
dominantly located at, or close to, the plasma membrane of VSMCs
using immunocytochemstry. These findings indicate that MARCKS is
expressed in mesenteric artery, and that it may have a functional role at
the plasma membrane of VSMCs.
3.2. MANS peptide induces vascular contractility
To investigate the role of MARCKS on vascular contractility we
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compared the effect of the selective MARCKS inhibitor, MANS peptide
(MANS, see Introduction and Methods for peptide details) [33,34] with
the α1-adrenoceptor agonist methoxoamine (MO) on isometric tension
recordings from segments of mouse mesenteric artery using wire
myography. Fig. 2 shows that bath applications of MO and MANS in-
duced concentration-dependent increases in contractility, with MANS
having a greater effective half maximal concentration (EC50) and
maximal effect (EMax) than MO of about 2-fold and 30% respectively.
Contractile responses to both MO and MANS were sustained during
continued application for 30 min and were reproducible following
multiple cycles of bath application and washing (Fig. S1). These results
suggest that MARCKS exerts an inhibitory action on contraction in
unstimulated vessels, and that removal of this inhibition action by
MANS induces vascular contractility in the absence of any receptor
stimulation. The potential physiological importance of MARCKS on
contractility is highlighted by the equivalence of contractions produced
by MANS and stimulation of the α1-adrenoceptor-mediated vasocon-
strictor pathway by MO.
3.3. Effect of reducing MARCKS expression on MANS- and vasoconstrictor-
evoked contractility
To investigate the selectivity of MANS and provide further evidence
that MARCKS regulates vascular contractility, we examined the effect of
reducing MARCKS expression on MANS- and vasoconstrictor-evoked
contractility using morpholino oligonucleotide technology previously
used to investigate other proteins in vascular contractility [31,32] (see
Methods for oligomer details).
In initial experiments, we tested whether MARCKS-targeted
morpholino oligomers reduce MARCKS expression. Fig. S2 shows that
fluorescein-tagged morpholino oligonucleotides were successfully
transfected into segments of mouse mesenteric artery after 48 h, and
that tissue lysates from vessels pre-treated with MARCKS-targeted
compared to scrambled sequence oligomers had significantly reduced
MARCKS expression by over 50%. Fig. S4 also shows that distribution of
MARCKS staining at, or close to, the plasma membrane of VSMCs was
reduced following pre-treatment of vessels with MARCKS-targeted oli-
gomers. In control experiments, Fig. S2 shows that expression of α-tu-
bulin or total protein levels were not altered by MARCKS-targeted oli-
gomers. In additional control experiments, we examined the effect of
MARCKS-targeted oligomers on expression levels of L-type (CaV1.2)
VGCCs, as activation of these channels are known to be important for
initiating vascular contractility [42–45]. Figs. S3 and S4 show that
expression of CaV1.2 protein levels and distribution of CaV1.2 staining
at, or close to, the plasma membrane of VSMCs was not altered in
vessels pre-treated with MARCKS-targeted compared to scrambled oli-
gomers. These results indicate that MARCKS-targeted oligomers pro-
duced substantial reduction of MARCKS expression but did alter α-tu-
bulin, total protein and CaV1.2 expression levels.
Figs. 3 and S5 show that the MANS-evoked contractions of mouse
mesenteric arteries pre-treated with scrambled oligomers for 48 h had
similar mean EC50 and Emax values to those obtained from vessels re-
corded from on the same day of isolation (Fig. 2). Figs. 3 and S5 also
show that, although the resting tension of mouse mesenteric artery
segments was not altered with pre-treatment of MARCKS-targeted
compared to scrambled oligomers, MANS-induced contractions were
significantly reduced by MARCKS-targeted oligomers, with mean EC50
and Emax values increased by about 3-fold and reduced by over 50%
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respectively.
Interestingly, Figs. 4 and S5 also show that contractions of mouse
mesenteric artery evoked by MO and the thromboxane receptor agonist
U46619 were inhibited in vessels pre-treated with MARCKS-targeted
compared to scrambled oligomers, with mean EC50 and Emax values
increased by about 3-fold and reduced by over 50% respectively.
It is possible that MARCKS-targeted oligomers reduce contractility
by inhibiting the activity of VGCCs and/or interfering with the Ca2+-
dependent contractile apparatus involving Ca2+-CaM, myosin light
chain kinase (MLCK), actin and myosin. Therefore, in control experi-
ments, we investigated the effect of MARCK-targeted oligomers on
contractions induced by high concentrations of KCl which induce con-
tractility by producing membrane depolarisation, activation of VGCCs,
Ca2+ influx and contraction and also by the Ca2+ ionophore ionomycin
that causes Ca2+ influx independently of stimulation of plasmalemmal
receptors or activation of VGCCs. Fig. S6 shows that contractions in-
duced by bath application of 60 mM and 120 mM KCl and 3 μM io-
nomycin were similar in vessels pre-treated with MARCKS-targeted and
scrambled oligomers. These findings indicate that knockdown of
MARCKS is unlikely to reduce MANS- and vasoconstrictor-evoked
contractility by blocking VGCC activity or decreasing the ability of
vessels to contract.
These results provide compelling evidence that MANS increases
vascular contractility by acting via MARCKS and indicates that
MARCKS is likely to have an important role in vasoconstrictor-mediated
contraction.
3.4. MANS-induced vascular contractility is inhibited by L- and T-type
VGCC blockers
In the next series of experiments, we investigated possible me-
chanisms involved in mediating MANS-induced contractions, to provide
an insight into how MARCKS may regulate vascular contractility. We
therefore investigated the effect of L- (CaV1.2) and T-type (CaV3.1/3.2
VGCC blockers on MANS-induced contraction of mouse mesenteric ar-
tery as both these VGCCs are thought to play a central role in mediating
vascular contractility [42–45]. Figs. 5 and S7 show that co-application
of the L-type channel blockers nicardipine, nifedipine and amlodipine
or the T-type channel blockers mibefradil, NNC 55–0396 and Ni2+
produced concentration-dependent inhibition of pre-contracted vas-
cular tone induced by a near maximal concentration of MANS
(100 μM). All blockers could produce 100% relaxation. These findings
suggest that vascular contractility induced by inhibition of MARCKS
requires activation of VGCCs, which may involve both L- and T-type
channel subtypes.
3.5. MANS has little effect on PLC activity or membrane potential
A potential hypothesis to explain why MANS induces contractility
via VGCCs is that by inhibiting MARCKS it causes MARCKS to release
PIP2, which then is available to drive PLC activity and subsequent
downstream stimulation of VGCCs. We explored this idea by studying
the effect of MANS on PLC activity by transfecting rat mesenteric artery
VSMCs primary cultured in low serum conditions (see Methods) with
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GFP-PLCδ-PH, a fluorescent biosensor with a high affinity for PIP2 and
IP3 [46] and then recording signal changes in fluorescent intensity units
at, or close to, the plasma membrane (Fm) and within the cytosol (Fc)
as previously described [40,41].
Fig. 6 shows that in unstimulated VSMCs, GFP-PLCδ-PH signals
were predominantly located at the plasma membrane with a mean
Fm:Fc ratio of about 15, as expected when PIP2 is mainly located at the
plasma membrane and there is limited cytosolic IP3. Fig. 6 illustrates
that bath application of 100 μM MANS for 10 min failed to alter this
signal distribution, whereas 10 μM MO induced translocation of GFP-
PLCδ-PH signals to the cytosol that resulted in reduction of the mean
Fm:Fc ratio by over 90%. These MO-induced signal changes are likely to
represent PLC-mediated PIP2 hydrolysis at the plasma membrane and
subsequent generation of cytosolic IP3 as previously described [40,41].
In support of these data, Fig. S8 shows that MO but not MANS altered
PIP2 levels at the plasma membrane measuring using the PIP2-specific
reporter GFP-tubby [46], as expected if MO induced PLC activity and
MANS did not. Moreover, Fig. S9 shows that pre-treatment of mouse
mesenteric artery segments with MANS did not significantly increase
IP3 levels measuring with an Elisa assay, whereas pre-treatment with
MO induced about a 5-fold increase in IP3 which is consistent with MO
stimulating PLC activity. These results suggest that unlike MO, MANS is
unlikely to produce significant effects on total PIP2 levels at the plasma
membrane or increase PLC activity,
Another possibility is that MANS induces contraction through pro-
ducing membrane depolarisation which leads to stimulation of VGCCs
and Ca2+ influx [1,2]. We investigated this idea by comparing the ef-
fects of MANS and MO on membrane potential using whole-cell patch
clamp recording under current-clamp conditions. Figs. 7A and C show
that in the presence of the bath and patch pipette solution conditions
used (see Methods) VSMCs had a resting membrane potential of about
−55 mV, and that bath application of MO induced a concentration-
dependent membrane depolarisation with a maximum effect of over
30 mV at above 30 μM. In contrast, Fig. 7B and C show that bath ap-
plication of 1–30 μM MANS failed to induce a change in membrane
potential whereas 100 μM MANS evoked a small depolarisation of less
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PH-mediated signals was predominantly expressed at
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dicates not significant.
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than 10 mV. These results suggest that distinct from MO, MANS is
unlikely to produce a significant effect on membrane potential in
VSMCs.
3.6. MARCKS and CaV1.2 subunits are co-localised in VSMCs
The above data suggests, it is unlikely that MANS induces contrac-
tion via increasing PLC activity or evoking membrane depolarisation.
We therefore examined if MARCKS may directly modulate VGCC ac-
tivity. We addressed this idea by investigating whether MANS and MO
modulate interactions between MARCKS and CaV1.2 subunits, which
are proposed to be the predominant VGCC subtype involved in produ-
cing vascular contractility [42–45] and are likely to be involved in
MANS-induced contractility (Figs. 5 and S7).
Fig. 8 show that immunocytochemical staining for MARCKS and
CaV1.2 were mainly located at, or close to, the plasma membrane of
mouse mesenteric artery VSMCs in unstimulated cells, and that there
was substantial co-localisation between these signals. Bath application
of 100 μM MANS and 10 μM MO reduced expression of MARCKS near
the plasma membrane which was accompanied by a noticeable increase
in MARCKS expression within the cytosol. In contrast, MANS and MO
failed to affect the expression distribution of CaV1.2. Furthermore, Fig.
S10 shows that proximity ligation assays (PLA) produced robust puncta
formation between MARCKS and CaV1.2 at, or close to, the plasma
membrane of unstimulated mouse mesenteric artery VSMCs, which was
reduced by over 70% following pre-treatment with 100 μM MANS and
10 μM MO.
These results suggest that MARCKS and CaV1.2 interact with each
other in unstimulated VSMCs, and that these interactions are reduced
by MANS and MO. Importantly, our data also suggest that reductions in
MARCKS-CaV1.2 interactions by MANS and MO are associated with
translocation of MARCKS from the plasma membrane to the cytosol.
3.7. MANS and MO alter interactions between PIP2, MARCKS, and CaV1.2
Since MARCKS is a well-established plasma membrane PIP2-binding
protein or PIPmodulin [11], we investigated if the reduction in
MARCKS-CaV1.2 interactions and translocation of MARCKS into the
cytosol produced by MANS and MO were accompanied by changes in
PIP2 associated with these two molecules. Using immunoprecipitation
and dot-blot methods as previously described [30], Fig. 9 shows that
there was a greater signal for PIP2 interactions with MARCKS than for
PIP2 with CaV1.2 in unstimulated rat mesenteric artery tissue lysates.
Following pre-treatment of vessels with 100 μM MANS and 10 μM MO
the strength of these signals was reversed, with greater binding ob-
served between of PIP2 and CaV1.2 than for PIP2 and MARCKS.
3.8. MANS increase VGCC activity through a PIP2-dependent mechanism
Our findings suggest that within MARCKS-CaV1.2 complexes, PIP2
Fig. 7. Effect of MANS and MO on membrane
potential of rat mesenteric artery VSMCs.
A and B, representative traces from two different
VSMCs with resting membrane potentials of
−58 mV and − 54 mV respectively. MO evoked
concentration-dependent depolarisations between
1 and 100 μM whereas MANS induced a mem-
brane depolarisation only at 100 μM. C, Mean data
of the effect of MO and MANS membrane poten-
tial. Data from N = at least 6 patches from n = 3
animals.
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may be predominantly bound to MARCKS and not CaV1.2. However,
upon stimulation with MANS and MO, MARCKS is translocated from
the plasma membrane to the cytosol leading to release of PIP2 that
binds to CaV1.2. This suggests that inhibition of MARCKS induces
vascular contractility by increasing VGCC activity through a PIP2-de-
pendent mechanism. We explored this idea by studying the effect of
MANS on VGCC current activity using Ba2+ as the charge carrier in rat
mesenteric artery VSMCs using whole-cell patch clamp recording under
voltage-clamp conditions.
Fig. 10A show that applying 300 ms voltage pulses from −80 mV to
+40 mV in 10 mV steps from a holding potential of −60 mV induced
whole-cell inward currents which activated at about −60 mV, reached
a peak amplitude at about +20 mV, and were inhibited by the VGCC
blocker nicardipine. These characteristics are consistent with activation
of whole-cell VGCC currents as previously described in VSMCs [47–50].
Bath application of 100 μM MANS produced a pronounced increase in
nicardipine-sensitive whole-cell inward currents, shifting the mean
activation curve to more negative membrane potentials and increasing
mean peak amplitude by over 50%. Moreover, Fig. 10B show that pre-
treatment of VSMCs with a high concentration of wortmannin (20 μM),
a PI4/PI5 kinase inhibitor that leads to depletion of PIP2 levels [51,52],
did not affect the activation curve of whole-cell inward currents but did
prevent MANS-induced negative shift in the mean activation curve and
increase in mean peak amplitude. This suggests that PIP2 is likely to
mediate the excitatory effect of MANS on VGCC activity.
To provide evidence that wortmannin reduces PIP2 levels, Fig. S11
shows that wortmannin reduced the plasma membrane signals of the
highly selective PIP2 biosensor GFP-Tubby and the PIP2/IP3 biosensor
GFP-PLCδ-PH in rat mesenteric artery VSMCs. Moreover, Fig. S11
shows that total PIP2 levels from tissue lysates of mouse mesenteric
artery measured using dot-blot analysis was reduced by pre-treatment
with wortmannin.
4. Discussion
The present study provides the first evidence that the PIP2-binding
protein MARCKS regulates vascular contractility and reveals its po-
tentially important role in mediating vasoconstrictor-induced
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after immunoprecipitation (IP) with either anti-
MARCKS (top panels) or anti-CaV1.2 antibodies
(bottom panels) from vessel segments pre-treated
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contractions. Our initial findings suggest that MARCKS regulates con-
traction by modulating the activity of VGCCs by PIP2. These results
identify novel cellular mechanisms involved in regulating vascular
contractility, which are likely to have important consequences for fu-
ture understanding of physiological and pathological vascular function.
4.1. MARCKS regulates vascular contractility
We show that MARCKS is expressed in mouse and rat mesenteric
artery VSMCs, where it is predominantly distributed at, or close to, the
plasma membrane. This is consistent with earlier studies from ferret
portal vein [26], human coronary artery [27–29] and rabbit and mouse
portal vein [30].
We used a well-established pharmacological intervention to in-
vestigate the role of MARCKS in vascular contractility. The selective
MARCKS inhibitor, MANS, evoked robust, sustained and reproducible
vascular contractions in mouse mesenteric arteries, which were
equivalent to contractions induced by stimulation of α1-adrenoceptors
by methoxamine (MO) and thromboxane receptors by U46619. MANS
is a selective inhibitory peptide, which corresponds to the myristoylated
N-terminal region that anchors MARCKS at the plasma membrane and
has been extensively used to investigate the function of MARCKS in
many different preparations [33–36]. MANS is used at relatively high
concentrations (up to 100 μM) as it acts by competing for endogenous
MARCKS at the plasma membrane and MARCKS is thought to have a
cellular concentration of about 10 μM (similar to the cellular con-
centration of PIP2) [33,34]. Thus, MANS is used at 10-fold greater
concentrations than endogenous MARCKS to produce sufficient in-
hibition.
To provide molecular evidence that the effects of MANS were not
produced through off-target actions, we showed that reducing MARCKS
expression levels and, distribution at, or close to, the plasma membrane
with MARCKS-targeted morpholino oligonucleotides greatly inhibited
MANS-evoked contractions. Contractions evoked by MANS and MO in
vessels pre-treated with scrambled morpholino oligomers had mean
EC50 and Emax values similar to values recorded in freshly isolated ar-
teries, and MARCKS-targeted oligomers did not alter expression of α-
tubulin or the expression and cellular distribution of CaV1.2 proteins.
These results suggest that the transfection process is unlikely to alter
vasoconstrictor-mediated responses or involvement of MARCKS in-
ferred through use of MANS, and importantly that MARCKS-targeted
oligomers have selectivity against MARCKS. All these findings increase
the validity to our approach. The lack of an effect of MARCKS-targeted
oligomers on expression levels and cellular distribution of CaV1.2 is
also of importance as we show that CaV1.2 is likely to be involved in
MARCKS-evoked contractions (see below).
A significant result was that contractions induced by MO and
U46619 were also substantially inhibited by MARCKS-targeted oligo-
mers, with changes in EC50 and Emax values equivalent to those ob-
served with MANS-evoked contractions. These striking findings pose an
interesting conflict; why does pharmacological inhibition of MARCKS
produce contractility whereas knockdown of MARCKS expression re-
duces vasoconstrictor-evoked contractility? These seemingly opposing
data can be explained if MARCKS exerts an inhibitory effect on con-
tractility in unstimulated vessels and that disinhibition of this action of
MARCKS is required for MANS- and vasoconstrictor-mediated con-
tractility. As such, disinhibition of this MARCKS inhibitory action in
unstimulated vessels by acute application or MANS or vasoconstrictor
agents (e.g. MO and U46619) induce contraction. However, following
knockdown of MARCKS, MANS and vasoconstrictor-stimulated disin-
hibition of MARCKS is curtailed leading to a reduction in contraction.
These ideas suggest is that disinhibition of MARCKS causing contraction
is unlikely to be a pharmacological phenomenon but is an important
physiological pathway which is necessary for vasoconstrictor-mediated
contractility.
It is possible that MARCKS-targeted oligomers may have reduced
MANS- and vasoconstrictor-mediated contractions by having non-se-
lective effects on the activity of VGCCs and/or by reducing the ability of
vessels to contract. However, this seems unlikely, contractions induced
by KCl and ionomyocin, which induce contractility through stimulating
VGCCs and providing direct Ca2+ influx to activate Ca2+-dependent
contractile mechanisms respectively were similar in vessels transfected
with scrambled and MARCKS-targeted oligomers. It might have been
expected that knockdown of MARCKS would alter resting tension,
produced in the normalisation process to represent a physiological
blood pressure of 100 mmHg, but our results showed that resting ten-
sion was not different between vessels pre-treated with scrambled and
MARCKS-targeted oligomers. This should perhaps be investigated in
future experiments using pressure myography which may provide
greater resolution.
In conclusion, these findings indicate that endogenous MARCKS has
a pronounced inhibitory action on vascular contractility which can be
modulated by direct inhibition of MARCKS and vasoconstrictor stimu-
lation. MARCKS has previously been shown to regulate proliferation
and migration of VSMCs and has been implicated in the progression of
intima hyperplasia [27–29]. However, this is first time that MARCKS
has been implicated in regulating contractility.
4.2. MANS evokes vascular contractility via activation of VGCCs
It is well-established that Ca2+ influx through activation of VGCCs
plays a central role in mediated vascular contraction involving two
VGCC subtypes, L-type (CaV1.2) and T-type (CaV3.1/3.2), with L-Type
VGCCs considered to have the predominant role in initiating vasocon-
strictor-mediated contraction [42–45]. Our results show that MANS-
evoked contractions were inhibited by several proposed selective L-type
and T-type VGCC blockers, with each agent able to produce complete
relaxation. The IC50 values for the blockers against MANS-evoked
contractions were relatively high compared to known values for these
channel subtypes [53–57]. This may be due to the blockers being ap-
plied to pre-contracted vessels and not pre-incubated before contraction
was induced and/or that multiple VGCC subtypes are involved. It is
therefore difficult to accurately determine from these experiments if
either or both L-type and T-type VGCCs are involved in mediating
MANS-evoked contractions. A potential discrimination is provided by
the effect of Ni2+, reported to offer T-type VGCCs selectivity at con-
centrations less than 50 μM [55], which blocked MANS-evoked con-
tractions with an IC50 of 250 μM suggesting a predominant role for L-
type VGCC subtype. What is certain is that activation of VGCCs play a
central role in the pathway whereby disinhibition of MARCKS by MANS
induces contraction.
4.3. MARCKS regulates interactions between VGCCs and PIP2
It is recognised that MANS, by competing with MARCKS at the
plasma membrane, induces translocation of MARCKS from the plasma
membrane to the cytosol that reduces electrostatic interactions between
MARCKS and PIP2 causing release of PIP2 into the local environment
[33,34]. We therefore considered that MANS may induce VGCC-medi-
ated contractions by inducing a rise in PIP2 levels, which acts as a
substrate for PLC activity to induce contraction via the familiar phos-
phatidylinositol transduction pathway. In addition, MANS may also
induce VGCCs and contraction by evoking a membrane depolarisation.
However, MANS failed to alter the distribution of the PIP2/IP3 bio-
sensor GFP-PLCδ-PH and PIP2-specific reporter GFP-tubby and had
little effect on membrane potential in VSMCs. This contrasts with sti-
mulation of α1-adrenoceptors, which induced a translocation of GFP-
PLCδ-PH and GFP-tubby from the plasma membrane to the cytosol in
VSMCs that is indicative of PLC activity [40,41], and induced a sig-
nificant membrane depolarisation. These findings are further supported
by previous evidence indicating that sequestered PIP2 by MARCKS does
not interfere with PLC activity [12,24].
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We next focused on the possibility that MANS and MO induce
contraction through regulating interactions between MARCKS, VGCCs,
and PIP2. We studied the L-type CaV1.2 subunit as this is considered the
dominant VGCC involved in initiating vascular contractility by MANS
from the pharmacological profile [42–45]. Using immunocytochemistry
and PLA, we clearly show that MARCKS-CaV1.2 interactions are present
in unstimulated VSMCs and that these associations occur at, or close to,
the plasma membrane. In addition, MANS and MO both cause dis-
sociation of MARCKS-CaV1.2 interactions and MARCKS to translocate
the cytosol. Moreover, we show that in unstimulated vessel segments
PIP2 was bound more to MARCKS than CaV1.2, but that this binding
profile was reversed following pre-treatment with MANS and MO.
These results are similar to earlier studies showing that the known in-
hibitors of MARCKS, CaM and PKC [15–26,30], and MO [30] lead to
translocation of MARCKS from the plasma membrane to the cytosol,
and that MO induces preferential changes in PIP2 binding at MARCKS-
TRPC1 interactions [30]. These findings provide further evidence that
MANS induces vascular contractility by causing disinhibition of an
endogenous MARCKS inhibitory pathway. Moreover, PIP2 imaging with
GFP-PLCδ-PH, GFP-tubby and dot-blots, indicate that redistribution of
PIP2 from MARCKS to CaV1.2 subunits and not changes in total PIP2
levels may be an important step in this pathway.
To provide further context to our ideas that MARCKS regulates
VGCCs via a PIP2-dependent mechanism, MANS induced an increase in
whole-cell VGCC currents in VSMCs through shifting the activation
curve to more negative membrane potentials and augmenting mean
peak amplitude. These MANS-mediated increases in VGCC currents
were prevented by pre-treatment of VSMCs with wortmannin which
depletes endogenous PIP2 levels. This is consistent with studies showing
that PIP2 facilitates L-, T-, and P-type VGCC activity in overexpression
systems [3–10]. High concentration of wortmannin (20 μM) depletes
PIP2 levels through inhibiting PI-4/PI-5 kinase-mediated PIP2 synthesis
(see Fig. S10) [4]. However, it should be noted that high concentrations
of wortmannin is also likely to inhibit myosin light chain kinase (MLCK)
and PI-3 kinase, and therefore due caution should be given to these
results.
Taken together, the present work indicates that MARCKS regulates
vascular contractility by modulating VGCC activity (see Fig. S12). In
unstimulated VSMCs, MARCKS forms interactions with CaV1.2 and acts
as a PIP2 buffer or PIPmodulin [11] to sequester local PIP2 levels that
reduces PIP2-mediated facilitation of VGCC activity. Disinhibition of
MARCKS by MANS leads to dissociation of MARCKS-CaV1.2 interac-
tions and translocation of MARCKS to the cytosol, which releases se-
questered PIP2 at the plasma membrane where it binds to and facilitates
VGCC activity to promote contraction. In the future it will be important
to identify if both L-type (CaV1.2) and T-type (CaV3.1/3.2) VGCC
subtypes are involved, and whether pore-forming α subunits and aux-
iliary subunits such as β and α2δ contribute to these responses. More-
over, a detailed examination of exogenous PIP2 and endogenous PIP2
actions on VGCC activity is required using respectively: water soluble
forms of PIP2 such as diC8-PIP2 and established techniques to deplete
endogenous PIP2 levels such as Danio rerio voltage-sensing phosphatase
(DrVSP) and rapamycin-FRB/FKBP-5′ phosphatase is required [58]. In
the longer term it will be important to reveal the structure of PIP2-
VGCC interaction sites.
4.4. Future implications for understanding cellular mechanisms regulating
vascular contractility
Our findings reveal that α1-adrenoceptor stimulation produced si-
milar actions to MANS on MARCKS-CaV1.2 interactions, MARCKS
translocation, and changes in PIP2 binding to MARCKS and CaV1.2 (Fig.
S12). In contrast, stimulation of α1-adrenoceptors evoked a substantial
membrane depolarisation of VSMCs whereas MANS had little effect on
membrane potential. It is generally considered that stimulation of Gq-
protein receptor-mediated pathways by vasoconstrictors induces
contractility through inducing membrane potential depolarisation
through modulation of ion channels such as cation, Cl−, and K+
channels which cause activation of VGCCs and Ca2+ influx [1,2,59].
The present study poses important questions about these established
vasoconstrictor-mediated pathways by suggesting that, in addition to
membrane depolarisation, these Gq-protein receptor-mediated path-
ways may also cause disinhibition of MARCKS to directly activate of
VGGCs to produce contraction. Essentially, VGCCs become receptor-
operated channels at the resting membrane potential through the fa-
cilitatory effect of PIP2 released from MARCKS, which shifts the acti-
vation threshold of VGCCs to more negative membrane potentials. The
idea that VGCCs may be receptor-operated channels and are activated
independently of membrane depolarisation is not new, some 30 years
ago, Nelson and colleagues presented evidence that vasoconstrictors
activate VGCCs held at resting membrane potentials [60]. There is no
doubt that this concept needs revisiting, such as does α1-adrenceptor-
induced contractions require MARCKS and are known Gq-protein re-
ceptor-mediated CaM and/or PKC pathways coupled to disinhibition of
MARCKS and regulation of contractility [26,30]. Whatever the outcome
of these future experiments, the present study provides the first evi-
dence that MARCKS has a critical role in regulating vascular con-
tractility and offers a potential new target for modulating contractility
in treating cardiovascular disease.
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